B-intervention	0	11	Venlafaxine
O	12	14	is
O	15	23	superior
O	24	26	to
B-control	27	36	clonidine
O	37	39	as
O	40	49	treatment
O	50	52	of
B-condition	53	56	hot
I-condition	57	64	flashes
O	65	67	in
O	68	74	breast
O	75	81	cancer
O	82	90	patients
O	90	91	-
O	91	92	-
O	92	93	a
O	94	100	double
O	100	101	-
O	101	106	blind
O	106	107	,
O	108	118	randomized
O	119	124	study
O	124	125	.

O	126	135	Classical
O	136	143	hormone
O	144	155	replacement
O	156	163	therapy
O	164	167	for
O	168	171	hot
O	172	179	flashes
O	180	182	is
O	183	198	contraindicated
O	199	201	in
O	202	208	breast
O	209	215	cancer
O	216	226	especially
O	227	229	in
O	230	239	endocrine
O	240	250	responsive
O	251	258	disease
O	258	259	.

O	260	262	In
O	263	264	a
O	265	271	double
O	271	272	-
O	272	277	blind
O	277	278	,
O	279	289	randomized
O	290	295	phase
O	296	299	III
O	300	305	study
O	305	306	,
B-eligibility	307	313	breast
I-eligibility	314	320	cancer
I-eligibility	321	329	patients
I-eligibility	330	339	suffering
I-eligibility	340	344	from
I-eligibility	345	348	hot
I-eligibility	349	356	flashes
I-eligibility	357	359	at
I-eligibility	360	365	least
I-eligibility	366	371	twice
I-eligibility	372	373	a
I-eligibility	374	377	day
I-eligibility	377	378	,
I-eligibility	379	382	who
I-eligibility	383	387	were
I-eligibility	388	391	not
I-eligibility	392	398	taking
I-eligibility	399	402	any
I-eligibility	403	413	medication
I-eligibility	414	421	against
I-eligibility	422	434	hypertension
I-eligibility	435	438	and
I-eligibility	439	449	depression
O	450	458	received
O	459	465	either
O	466	475	clonidine
O	476	477	0
O	477	478	.
O	478	481	075
O	482	484	mg
O	485	490	twice
O	491	492	a
O	493	496	day
O	497	499	or
O	500	511	venlafaxine
O	512	514	37
O	514	515	.
O	515	516	5
O	517	519	mg
O	520	525	twice
O	526	527	a
O	528	531	day
O	532	535	for
O	536	537	4
O	538	543	weeks
O	543	544	.

O	545	548	The
O	549	556	primary
O	557	560	end
O	561	566	point
O	567	570	was
O	571	578	defined
O	579	581	as
O	582	585	the
B-outcome-Measure	586	595	frequency
I-outcome-Measure	596	598	of
I-outcome-Measure	599	602	hot
I-outcome-Measure	603	610	flashes
O	611	616	after
O	617	618	4
O	619	624	weeks
O	625	627	of
O	628	637	treatment
O	637	638	.

O	639	640	A
O	641	645	self
O	645	646	-
O	646	654	reported
O	655	656	1
O	656	657	-
O	657	661	week
O	662	665	hot
O	666	671	flash
O	672	675	and
O	676	681	other
O	682	689	symptom
O	690	703	questionnaire
O	704	708	were
O	709	713	kept
O	714	720	before
O	721	724	the
O	725	730	start
O	731	733	of
O	734	743	treatment
O	744	749	until
O	750	753	the
O	754	757	end
O	758	760	of
O	761	770	treatment
O	771	777	course
O	777	778	.

O	779	783	From
O	784	789	April
O	790	794	2002
O	795	797	to
O	798	805	October
O	806	810	2004
O	810	811	,
B-total-participants	812	814	80
O	815	823	patients
O	824	828	were
O	829	838	recruited
O	839	841	of
O	842	846	whom
B-total-participants	847	849	64
O	850	854	were
O	855	865	assessable
O	866	869	for
O	870	878	efficacy
O	879	887	analyses
O	887	888	.

B-control-participants	889	895	Thirty
I-control-participants	895	896	-
I-control-participants	896	901	three
O	902	910	received
O	911	920	clonidine
O	921	924	and
B-intervention-participants	925	927	31
O	928	939	venlafaxine
O	939	940	,
O	941	945	nine
O	946	954	patients
O	955	962	stopped
O	963	968	early
O	969	976	because
O	977	979	of
O	980	984	side
O	984	985	-
O	985	992	effects
O	993	996	and
O	997	1002	seven
O	1003	1011	withdrew
O	1012	1019	consent
O	1019	1020	.

O	1021	1023	At
O	1024	1027	the
O	1028	1031	end
O	1032	1034	of
O	1035	1044	treatment
O	1045	1049	week
O	1050	1051	4
O	1051	1052	,
O	1053	1056	the
B-outcome	1057	1063	median
I-outcome	1064	1067	hot
I-outcome	1068	1073	flash
I-outcome	1074	1083	frequency
O	1084	1091	dropped
O	1092	1094	by
B-iv-cont-median	1095	1096	7
I-iv-cont-median	1096	1097	.
I-iv-cont-median	1097	1098	6
O	1099	1102	hot
O	1103	1110	flashes
O	1111	1114	per
O	1115	1118	day
O	1119	1122	for
O	1123	1131	patients
O	1132	1141	receiving
O	1142	1153	venlafaxine
O	1154	1157	and
B-cv-cont-median	1158	1159	4
I-cv-cont-median	1159	1160	.
I-cv-cont-median	1160	1162	85
O	1163	1166	hot
O	1167	1174	flashes
O	1175	1178	per
O	1179	1182	day
O	1183	1186	for
O	1187	1192	those
O	1193	1202	receiving
O	1203	1212	clonidine
O	1213	1214	(
O	1214	1215	P
O	1216	1217	=
O	1218	1219	0
O	1219	1220	.
O	1220	1223	025
O	1223	1224	)
O	1224	1225	.

O	1226	1237	Venlafaxine
O	1238	1240	is
O	1241	1254	significantly
O	1255	1259	more
O	1260	1269	effective
O	1270	1272	in
O	1273	1281	reducing
O	1282	1285	the
O	1286	1295	frequency
O	1296	1298	of
O	1299	1302	hot
O	1303	1310	flashes
O	1311	1313	in
O	1314	1320	breast
O	1321	1327	cancer
O	1328	1336	patients
O	1337	1341	than
O	1342	1351	clonidine
O	1351	1352	.
